Bristol-Myers Squibb Company  Announces Four-Year Follow-up with Empliciti Plus Lenalidomide/Dexamethasone  in Patients with Advanced Multiple Myeloma Shows Long-term Efficacy in ELOQUENT-2 Trial #EHA2017